Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 3/20 | 0.46 |
| ▸ | DRD3 | P35462 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.45 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15765888 | 1.00 | KMT2A (0.55) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL1470556 | 1.00 | KMT2A (0.55) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL1470555 | 1.00 | KMT2A (0.55) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL556530 | 1.00 | KMT2A (0.55) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL4369305 | 0.91 | DRD2 (0.56) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL4372426 | 0.91 | DRD2 (0.56) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL4369301 | 0.91 | DRD2 (0.56) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL4372414 | 0.91 | DRD2 (0.56) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL4369297 | 0.91 | DRD2 (0.56) | KMT2AL3MBTL1KCNA3SCN4AMEN1 | |
| SCHEMBL13349121 | 0.90 | KMT2A (0.54) | KMT2AL3MBTL1KCNA3SCN4AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20210284637-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2021-09-16 | — | — | US | disclosed |
| US-10981906-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | ACLARIS THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20190135808-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | ACLARIS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-2420502-A1 | FUSED PYRROLOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2012-02-22 | — | — | EP | disclosed |
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120034250-A1 | CONDENSED PYRROLOPYRIDINE DERIVATIVE | JAK2, JAK1, JAK3 | KMT2A 2746/4885L3MBTL1 4102/4885KCNA3 2070/4885 |
| US-10981906-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | KMT2A 1412/4885L3MBTL1 3761/4885KCNA3 1175/4885 |
| US-12281111-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | KMT2A 1412/4885L3MBTL1 3761/4885KCNA3 1175/4885 |
| US-20260062410-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | KMT2A 1863/4885L3MBTL1 4137/4885KCNA3 1246/4885 |
| US-20240067643-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | KMT2A 1412/4885L3MBTL1 3761/4885KCNA3 1175/4885 |
| US-20210284637-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | KMT2A 1412/4885L3MBTL1 3761/4885KCNA3 1175/4885 |
| US-11739086-B2 | Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same | JAK3, JAK1, JAK2 | KMT2A 1412/4885L3MBTL1 3761/4885KCNA3 1175/4885 |
| US-20190135808-A1 | SUBSTITUTED PYRROLOPYRIDINE JAK INHIBITORS AND METHODS OF MAKING AND USING THE SAME | JAK3, JAK1, JAK2 | KMT2A 1412/4885L3MBTL1 3761/4885KCNA3 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.